Inflammatory Bowel Disease (IBD) Epidemiology Forecast 2025-2034

IBD, which includes Crohn's disease and ulcerative colitis, is a chronic illness that causes inflammation of the digestive tract. It causes symptoms like fatigue, weight loss, diarrhea, and stomach pain. The number of incident cases of IBD worldwide increased by 88.30% between 1990 and 2021. In 2021, there were 4.45 cases for every 100,000 people across the globe.

Inflammatory Bowel Disease (IBD) Epidemiology Forecast Report Coverage

The “Inflammatory Bowel Disease (IBD) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of inflammatory bowel disease. It projects the future incidence and prevalence rates of inflammatory bowel disease across various populations. The study covers age, gender, and type as major determinants of the inflammatory bowel disease affected population. The report highlights patterns in the prevalence of inflammatory bowel disease over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of inflammatory bowel disease (IBD) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Inflammatory Bowel Disease (IBD) Disease Overview

Crohn's disease and ulcerative colitis are the two main chronic inflammatory gastrointestinal (GI) disorders that make up inflammatory bowel disease (IBD). While ulcerative colitis only affects the inner lining of the colon and rectum, Crohn's disease can affect any part of the GI tract and cause deep tissue inflammation. Although the precise cause of IBD is unknown, it is thought to be caused by an aberrant immune response brought on by environmental and genetic factors. Abdominal pain, chronic diarrhea, fatigue, malnourishment, and weight loss are among the symptoms, which can get worse over time.

Inflammatory Bowel Disease (IBD): Treatment Overview

Inflammatory bowel disease involves reducing inflammation, controlling symptoms, and avoiding complications. It usually consists of immunosuppressants, biologic treatments that target the immune system, and anti-inflammatory medications (like corticosteroids and aminosalicylates). Changes in diet and lifestyle can help reduce symptoms and enhance quality of life. In extreme situations, surgery might be necessary to treat complications like strictures and fistulas or remove damaged intestinal segments. The severity of the disease, the patient's response, and the location can influence the treatment plans significantly.

Epidemiology

The Inflammatory Bowel Disease (IBD) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for inflammatory bowel disease by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for inflammatory bowel disease and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to a study, around 4.9 million cases of IBD were reported globally in 2019, with the highest numbers occurring in China and the USA (911,405, and 762,890 cases, respectively, or 66.9 and 245.3 cases per 100,000 people). Global age-standardized rates of mortality, DALYs, and prevalence declined between 1990 and 2019.
• A study indicated that up to 25% of patients will develop IBD by adolescence, even though most cases occur in people between the ages of 15 and 30. With a second peak of 10% to 15% developing IBD after age 60, there seems to be a bimodal distribution.
• Another study revealed that the ratio of young female patients to young adults varies greatly by country, ranging from 26% to 62%. The percentage of females among young adults with IBD rose by 0.24%, suggesting that the condition is becoming more common in women than in men.

Country-wise Inflammatory Bowel Disease (IBD) Epidemiology

The inflammatory bowel disease (IBD) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of inflammatory bowel disease (IBD) varies between countries owing to the differences in factors such as obesity, tobacco smoking, diabetes and others. According to the U.S. Centers for Disease Control and Prevention, in the United States, the prevalence of inflammatory bowel disease (IBD) varies by group and is estimated to be between 2.4 and 3.1 million in the United States. Both the prevalence of IBD and medical expenses are increasing. IBD-related medical expenses in the United States totaled roughly USD 8.5 billion in 2018.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of inflammatory bowel disease based on several factors.
• Inflammatory Bowel Disease (IBD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of inflammatory bowel disease (IBD) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of inflammatory bowel disease (IBD) epidemiology in the 8 major markets?
• What will be the total number of patients with inflammatory bowel disease (IBD) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of inflammatory bowel disease (IBD) in the 8 major markets in the historical period?
• Which country will have the highest number of inflammatory bowel disease (IBD) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of inflammatory bowel disease (IBD) during the forecast period of 2025-2034?
• What are the currently available treatments for inflammatory bowel disease (IBD)?
• What are the disease risks, signs, symptoms, and unmet needs of inflammatory bowel disease (IBD)?

This product will be delivered within 3-5 business days.